Fezolinetant significantly reduces vasomotor symptoms in post-menopausal women
1. Fezolinetant 30 mg and 45 mg significantly reduced the frequency and severity of vasomotor symptoms compared to placebo. 2. The beneficial effects of fezolinetant on vasomotor symptoms were sustained for up to 52 weeks. Evidence Rating Level: 1 (Excellent) Study Rundown: Vasomotor symptoms can substantially negatively impact the quality of life of post-menopausal women.